免疫检查点抑制剂治疗后疾病进展的临床特征及预后因素分析
摘要
关键词
全文:
PDF镜像
|参考
[1]Sharma P, Allison J P. The future of immune checkpoint therapy. Science, 2015, 348(6230): 56-61.
[3]Sharma P, Hu-Lieskovan S, Wargo J A, et al. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell, 2017, 168(4): 707-723.
[4]Schoenfeld A J, Hellmann M D. Acquired resistance to immune checkpoint inhibitors. Cancer Cell, 2020, 37(4): 443-455.
[5]Liu T T, et al. Research progress on the potential mechanisms of hyper-progressive disease in immune checkpoint blockade therapy of solid tumors. Chinese Journal of Lung Cancer, 2025, 28(9): 700-709.
[6]Kanjanapan Y, Guduguntla G, Varikara A K, et al. Hyperprogressive disease (HPD) in solid tumours receiving immune checkpoint inhibitors in a real-world setting. Technology in Cancer Research and Treatment, 2023, 22: 1-9.
[7]Vesely M D, Zhang T, Chen L. Resistance mechanisms to immune checkpoint inhibitors: updated insights. Molecular Cancer, 2025, 24: 20.
[8]Karagiannis P, et al. Oncogenic signalling pathways in cancer immunotherapy: leader or follower in this delicate dance? International Journal of Molecular Sciences, 2025, 26(9): 4393.
[9]Zhu S, et al. Mechanisms, combination therapy, and biomarkers in cancer immunotherapy resistance. Cell Communication and Signaling, 2024, 22: 338.
[11]Şen G A, Şentürk Öztaş N, Değerli E, et al. Hyperprogressive disease in patients with advanced cancer treated with immune checkpoint inhibitors. Clinical and Translational Oncology, 2024, 27: 736-744.
[13]Garralda E, et al. Towards evidence-based response criteria for cancer immunotherapy. Nature Communications, 2023, 14: 3001.
[14]Seymour L, Bogaerts J, Perrone A, et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. The Lancet Oncology, 2017, 18(3): e143-e152.
[15]中国临床肿瘤学会免疫治疗专家委员会. 免疫检查点抑制剂临床应用指南. 北京: 人民卫生出版社, 2023.
[16]庞北川, 谭煜炜, 李友伟, 等. 肝细胞癌免疫治疗超进展潜在分子机制及预测因素研究进展. 中国普外基础与临床杂志, 2025, 32(7): 911-915.
(0 摘要 Views, 0 PDF Downloads)
Refbacks
- 当前没有refback。